A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

被引:88
|
作者
Kastritis, Efstathios [1 ]
Terpos, Evangelos [1 ]
Roussou, Maria [1 ]
Gavriatopoulou, Maria [1 ]
Pamboukas, Constantinos [1 ]
Boletis, Ioannis [1 ]
Marinaki, Smaragda [1 ]
Apostolou, Theofanis [1 ]
Nikitas, Nikitas [1 ]
Gkortzolidis, Georgios [1 ]
Michalis, Eurydiki [1 ]
Delimpasi, Sossana [1 ]
Dimopoulos, Meletios A. [1 ]
机构
[1] Univ Athens, Sch Med, Dept Clin Therapeut, Athens 11528, Greece
关键词
LIGHT-CHAIN AMYLOIDOSIS; NATRIURETIC PEPTIDE; MELPHALAN; COMBINATION; THALIDOMIDE; EFFICACY; INVOLVEMENT; BORTEZOMIB; MYELOMA;
D O I
10.1182/blood-2011-12-396903
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this phase 1/2 study, we explored the feasibility and activity of an oral regimen of lenalidomide with low-dose dexamethasone and low-dose oral cyclophosphamide (RdC) in patients with primary systemic light chain amyloidosis. RdC was given for up to 12 cycles in prespecified cohorts at escalated doses: 13 patients were treated in phase 1 and 24 in phase 2; 65% were previously untreated, and most had renal and/or cardiac involvement and elevated cardiac biomarkers. Lenalidomide 15 mg/d and cyclophosphamide 100 mg/d were further evaluated in phase 2. On intention to treat, 20 (55%) patients achieved a hematologic response, including 3 (8%) complete remissions. Hematologic responses were seen at all dose levels and in 4 of 5 patients who had received bortezomib previously. An organ response was recorded in 22% of patients on intention-to-treat and in 40% of patients who survived at least 6 months. The median time to progression was 10 months and the 2-year survival was 41%. Fatigue, nonneutropenic infections, and rash were the most common toxicities. The results of the present study show that RdC is an oral regimen with activity in primary systemic light chain amyloidosis and may be an additional treatment option, especially for patients with preserved organ function or for patients who cannot receive or who relapse after bortezomib. This study is registered at www.clinicaltrials.gov as NCT00981708. (Blood. 2012;119(23):5384-5390)
引用
收藏
页码:5384 / 5390
页数:7
相关论文
共 50 条
  • [21] Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study
    Suzuki, Kenshi
    Shinagawa, Atsushi
    Uchida, Toshiki
    Taniwaki, Masafumi
    Hirata, Hirokazu
    Ishizawa, Kenichi
    Matsue, Kosei
    Ogawa, Yoshiaki
    Shimizu, Takayuki
    Otsuka, Maki
    Matsumoto, Morio
    Iida, Shinsuke
    Terui, Yasuhito
    Matsumura, Itaru
    Ikeda, Takashi
    Takezako, Naoki
    Ogaki, Yumi
    Midorikawa, Shuichi
    Houck, Vanessa
    Ervin-Haynes, Annette
    Chou, Takaaki
    CANCER SCIENCE, 2016, 107 (05) : 653 - 658
  • [22] A Phase I/II Study of Lenalidomide (R) with Low Dose Dexamethasone (d) and Cyclophosphamide (C) for Patients with Primary Systemic (AL) Amyloidosis
    Kastritis, Efstathios
    Roussou, Maria
    Migkou, Magdalini
    Pamboukas, Konstantinos
    Gavriatopoulou, Maria
    Gogos, Dimitrios
    Liapis, Konstantinos
    Michalis, Eurydiki
    Delimpasi, Sosana
    Psimenou, Erasmia
    Toumanidis, Savvas
    Kontoyannis, Sofocles A.
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    BLOOD, 2009, 114 (22) : 177 - 178
  • [23] Bortezomib and Low-Dose Dexamethasone with or without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma: Final Results of a National Multicenter Randomized Controlled Phase III Study
    Kropff, Martin
    Vogel, Martin
    Kreter, Andrea
    Schlag, Rudolf
    Mueller, Lothar
    Weide, Rudolf
    Knauf, Wolfgang
    Decker, Thomas
    Fiechtner, Heinrich
    Kojouharoff, Georgi
    Kremers, Stephan
    Berdel, Wolfgang E.
    BLOOD, 2014, 124 (21)
  • [24] LOW-DOSE RECOMBINANT INTERLEUKIN-2 AND LOW-DOSE CYCLOPHOSPHAMIDE IN METASTATIC BREAST-CANCER
    SPICER, DV
    KELLEY, A
    HERMAN, R
    DEAN, G
    STEVENSON, L
    MITCHELL, MS
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1992, 34 (06) : 424 - 426
  • [25] EFFECTIVENESS AND TOLERABILITY OF LOW-DOSE CYCLOPHOSPHAMIDE AND LOW-DOSE INTRAVENOUS INTERLEUKIN-2 DISSEMINATED MELANOMA
    MITCHELL, MS
    KEMPF, RA
    HAREL, W
    SHAU, H
    BOSWELL, WD
    LIND, S
    BRADLEY, EC
    JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (03) : 409 - 424
  • [26] Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma
    Kropff, Martin
    Bisping, Guido
    Schuck, Elke
    Liebisch, Peter
    Lang, Nicola
    Hentrich, Markus
    Dechow, Tobias
    Kroeger, Nicolaus
    Salwender, Hans
    Metzner, Bernd
    Sezer, Orhan
    Engelhardt, Monika
    Wolf, Hans-Heinrich
    Einsele, Hermann
    Volpert, Sarah
    Heinecke, Achim
    Berdel, Wolfgang E.
    Kienast, Joachim
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (03) : 330 - 337
  • [27] LENALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN RELAPSE/ REFRACTORY MULTIPLE MYELOMA: A RETROSPECTIVE STUDY
    Firatli-Tuglular, T.
    Noyan-Atalay, F.
    Eser, A.
    Toptas, T.
    Pepedil, F.
    Kaygusuz-Atagunduz, I.
    Adiguzel, C.
    HAEMATOLOGICA, 2013, 98 : 614 - 615
  • [28] LOW-DOSE CYCLOPHOSPHAMIDE TREATMENT ON THE MYELOMA
    ISOBE, T
    HORIMATSU, T
    MATSUMOTO, J
    KISHIHARA, M
    FUJITA, T
    ACTA HAEMATOLOGICA JAPONICA, 1979, 42 (04): : 678 - 683
  • [29] DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma
    Khouri, Jack
    Faiman, Beth M.
    Grabowski, Dale
    Mahfouz, Reda Z.
    Khan, Shahper N.
    Wei, Wei
    Valent, Jason
    Dean, Robert
    Samaras, Christy
    Jha, Babal K.
    Lazarus, Hillard
    Campagnaro, Erica L.
    Malek, Ehsan
    Reed, Janice
    Karam, Mary Ann
    Hamilton, Kimberly
    Fada, Sherry
    Kalaycio, Matt
    Liu, Hien
    Sobecks, Ronald
    Saunthararajah, Yogen
    Chew, Yap
    Orloff, Mohammed
    Reu, Frederic J.
    SEMINARS IN HEMATOLOGY, 2021, 58 (01) : 45 - 55
  • [30] LOW-DOSE ORAL PROPRANOLOL
    DAVIES, R
    PICKERING, TG
    MORGANTI, A
    BIANCHETTI, G
    MORSELLI, PL
    ROMANKIEWICZ, J
    LARAGH, JH
    LANCET, 1978, 1 (8068): : 827 - 828